Last reviewed · How we verify
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of digestive carcinoma.
Details
| Lead sponsor | China Medical University, China |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 1 |
| Start date | Fri Jul 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Dec 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- PD-1 Antibody
- DC-Cell
- NK-Cell
- Gastrointestinal Tumours
Interventions
- Pembrolizumab
- Nivolumab
- Sintilimab
- Toripalimab
- Camrelizumab
- Tislelizumab
- NK-Cell or DC-Cell